• linkedin
  • Increase Font
  • Sharebar

    Pearls to optimize safety, success with biologics

    Safety issues top priority for therapeutic selection and follow-up

     

    Considerations with common comorbidities

    The individualized treatment decision also takes into account diseases that are seen more frequently in patients with psoriasis, and those include inflammatory bowel disease (IBD), psoriatic arthritis, and cardiovascular disease.

    Because infliximab, adalimumab, and ustekinumab have indications for IBD, they are preferred for patients with that history, whereas IL-17A antagonists are generally less favored considering rare reports linking them with IBD development or exacerbation.

    Dr. Sobell notes that all of the biologics except ixekizumab are indicated for treatment of psoriatic arthritis. Based on available experience and assuming absence of any contraindications, his preference for treating patients with comorbid psoriatic arthritis is to use a TNF-α antagonist.

    “The IL-17A drugs have also demonstrated solid success treating psoriatic arthritis, and I expect ixekizumab will be approved for that indication soon,” Dr. Sobell says.
    “Reported results are least robust for ustekinumab, and that is consistent with my personal experience.”

    Dr. Sobell also favors a TNF-α antagonist for patients with coronary artery disease. That preference takes into account a retrospective analysis of psoriasis patients showing a 48% reduction in myocardial infarction risk with use of a TNF-α antagonists compared with topical agents.

    “Based on a shared inflammatory pathway, psoriasis itself is a risk factor for cardiovascular disease, and ongoing studies are investigating whether TNF-α antagonists have cardioprotective benefits,” Dr. Sobell says.
    Getting started

    In order to decide candidacy for biologic treatment and to obtain baseline information for judging treatment response, patients are asked about severity of their symptoms, particularly itch but also pain. They are also assessed for body surface area (BSA) and anatomic areas of involvement, and their disease severity is rated using the 5-point Physicians Global Assessment (PGA) scale.

    “Location of disease is extremely important and not just area of involvement. There is a lower threshold for using a biologic agent for psoriasis affecting the hands, feet, genital area, or scalp,” Dr. Sobell says.

    The initial laboratory work-up includes a complete blood count, full chemistry panel with liver function tests and screens for TB and hepatitis as well as pregnancy if appropriate. Dr. Sobell also obtains a geographic-directed history for deep fungal infection and noted that no patient on a biologic should be given a live vaccine.  

    Prior to treatment initiation, patients also receive extensive face-to-face education supplemented with brochures and information about online resources, particularly from the manufacturers and the National Psoriasis Foundation.

    “The manufacturers are also a good resource for providing staff with guidance on obtaining prior authorization, which can be particularly frustrating,” Dr. Sobell says, adding that the process becomes easier over time and seems to have improved as more treatments have become available.

    Patients are evaluated for response at 12 weeks, taking into account that the peak benefit with some biologics may not be reached for another four to 12 weeks. The decision to continue is based on the physician’s and patient’s satisfaction with the improvement achieved, although for Medicare patients, PQRS guidelines suggest a PGA score of clear or almost clear or BSA <3%.

    During the first year after treatment initiation, Dr. Sobell sees patients every three months and then transitions to a semi-annual follow-up schedule.
    “In addition to monitoring efficacy and safety by conducting a complete review of systems, I also continue to stress adherence to the injection protocol at each visit and make sure patients are being followed by their primary care physician,” he said.

    A full skin examination is done at least once a year, and the initial laboratory tests as well as a TB screen are also repeated annually.

    Disclosure: Dr. Sobell is an investigator, consultant and speaker for a number of companies that market biologics for inflammatory skin diseases.

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow